OT mobile menu

Search form


ASCO 2014

ASCO 2014

The anti-programmed-death-receptor-1 (PD-1) antibody, pembrolizumab (MK-3475), is effective and tolerable in patients with metastatic melanoma who have previously received another metastatic melanoma therapy.

The use of bevacizumab or cetuximab, in combination with either the FOLFOX  (leucovorin/5-fluorouracil/ oxaliplatin) or FOLFIRI (leucovorin/5-fluoruracil/irinotecan) chemotherapy regimen, achieved similarly effective overall survival (OS)

Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.

In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.

Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where a new agent, pidilizumab, fits into the picture.

From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.

CHICAGO—Addition of the immunomodulatory agent lenalidomide to R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) may reduce the negative prognostic significance of the non-GCB (germinal center B-cell) phenotyp


Subscribe to ASCO 2014 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.